Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline
Public ClinicalTrials.gov record NCT00506415. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon® 10 and 15 cm^2 Patch in Patients With Mild to Moderate Alzheimer's Disease (AD) Showing Functional and Cognitive Decline
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to support the optimal use of rivastigmine patch in long-term treatment of Alzheimer's Disease in patients demonstrating functional and cognitive decline at the target maintenance dose of rivastigmine patch 10 cm\^2.
Study identification
- NCT ID
- NCT00506415
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,584 participants
Conditions and interventions
Conditions
Interventions
- Rivastigmine 5 cm^2 Drug
- Rivastigmine 10 cm^2 Drug
- Rivastigmine 15 cm^2 Drug
- Placebo to 15 cm^2 patch Drug
- Placebo to 10 cm^2 patch Drug
Drug
Eligibility (public fields only)
- Age range
- 50 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2007 (Type not available)
- Primary completion
- May 2011 (Actual)
- Completion
- May 2011 (Actual)
- Last update posted
- Sep 19, 2012
2007 – 2011
United States locations
- U.S. sites
- 65
- U.S. states
- 22
- U.S. cities
- 64
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis investigative site | Birmingham | Alabama | 35294 | — |
| Novartis investigative site | Gilbert | Arizona | 85234 | — |
| Novartis investigative site | Phoenix | Arizona | 85004 | — |
| Novartis investigative site | Sun City | Arizona | 85351 | — |
| Novartis investigative site | Anaheim | California | 92804 | — |
| Novartis investigative site | Carson | California | 90746 | — |
| Novartis investigative site | Costa Mesa | California | 92626 | — |
| Novartis investigative site | Fullerton | California | 92835 | — |
| Novartis investigative site | La Habra | California | 90631 | — |
| Novartis investigative site | La Jolla | California | 92037 | — |
| Novartis investigative site | National City | California | 91950 | — |
| Novartis investigative site | Redlands | California | 92374 | — |
| Novartis investigative site | San Francisco | California | 94115 | — |
| Novartis investigative site | Fort Collins | Colorado | 80524 | — |
| Novartis investigative site | Longmont | Colorado | 80501 | — |
| Novartis investigative site | Boca Raton | Florida | 33431 | — |
| Novartis investigative site | Bradenton | Florida | 32405 | — |
| Novartis investigative site | Deerfield Beach | Florida | 33064 | — |
| Novartis investigative site | Delray Beach | Florida | 33445 | — |
| Novartis investigative site | Fort Lauderdale | Florida | 33308 | — |
| Novartis investigative site | Gainesville | Florida | 32610 | — |
| Novartis investigative site | Miami Beach | Florida | 33140 | — |
| Novartis investigative site | Pompano Beach | Florida | 33060 | — |
| Novartis investigative site | Port Charlotte | Florida | 33952 | — |
| Novartis investigative site | Sunrise | Florida | 33351 | — |
| Novartis investigative site | West Palm Beach | Florida | 33407 | — |
| Novartis investigative site | Atlanta | Georgia | 30341-4155 | — |
| Novartis investigative site | Macon | Georgia | 31201 | — |
| Novartis Investigative Site | Honolulu | Hawaii | 96817 | — |
| Novartis investigative site | Chicago | Illinois | 60611 | — |
| Novartis investigative site | Springfield | Massachusetts | 01104 | — |
| Novartis investigative site | Flint | Michigan | 48532 | — |
| Novartis investigative site | Flushing | Michigan | 48433 | — |
| Novartis investigative site | Roseville | Michigan | 48066 | — |
| Novartis investigative site | Traverse City | Michigan | 49684-2340 | — |
| Novartis investigative site | Hattiesburg | Mississippi | 39401 | — |
| Novartis investigative site | Ocean Springs | Mississippi | 39564 | — |
| Novartis investigative site | Columbia | Missouri | 65201 | — |
| Novartis investigative site | St Louis | Missouri | 63141 | — |
| Novartis investigative site | Flemington | New Jersey | 08822 | — |
| Novartis investigative site | Nutley | New Jersey | 07110 | — |
| Novartis investigative site | Somerset | New Jersey | 08873 | — |
| Novartis investigative site | Albany | New York | 12208 | — |
| Novartis investigative site | Syracuse | New York | 13210-1853 | — |
| Novartis investigative site | Greensboro | North Carolina | 27401 | — |
| Novartis investigative site | Morganton | North Carolina | 28655 | — |
| Novartis investigative site | Winston-Salem | North Carolina | 27103-4019 | — |
| Novartis investigative site | Winston-Salem | North Carolina | 27103 | — |
| Novartis investigative site | Canton | Ohio | 44718 | — |
| Novartis investigative site | Columbus | Ohio | 43220 | — |
| Novartis investigative site | Corvallis | Oregon | 97330 | — |
| Novartis investigative site | Portland | Oregon | 97225 | — |
| Novartis investigative site | Beaver | Pennsylvania | 15009-1957 | — |
| Novartis investigative site | Erie | Pennsylvania | 16506 | — |
| Novartis investigative site | Greensburg | Pennsylvania | 15601 | — |
| Novartis investigative site | Pittsburgh | Pennsylvania | 15243 | — |
| Novartis investigative site | Beaufort | South Carolina | 29902 | — |
| Novartis investigative site | Summerville | South Carolina | 29485 | — |
| Novartis investigative site | Brentwood | Tennessee | 37027-5240 | — |
| Novartis investigative site | Nashville | Tennessee | 37203 | — |
| Novartis investigative site | Dallas | Texas | 75231 | — |
| Novartis investigative site | Fort Worth | Texas | 76107 | — |
| Novartis investigative site | Irving | Texas | 75062 | — |
| Novartis investigative site | Charleston | West Virginia | 25304 | — |
| Novartis investigative site | Huntington | West Virginia | 25701 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 79 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00506415, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 19, 2012 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00506415 live on ClinicalTrials.gov.